SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant Passive Stake in VOR Biopharma Inc.
Beneficial Ownership Disclosure
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.3% of VOR Biopharma Inc.'s common stock as of December 31, 2024.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 6,419,633 shares of VOR Biopharma Inc. common stock.
- This ownership represents 9.3% of the total outstanding common stock of VOR Biopharma Inc.
- FMR LLC holds sole voting power over 6,413,149 shares and sole dispositive power over 6,419,633 shares.
- Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is deemed to beneficially own the same 6,419,633 shares with sole dispositive power.
- The filing is an Amendment No. 4 to a Schedule 13G, indicating a passive investment without intent to influence control of the issuer.
- The Johnson family, including Abigail P. Johnson, are the predominant owners of Series B voting common shares of FMR LLC, representing 49% of its voting power, and have a voting agreement for these shares.
Sentiment
Score: 7
Explanation: The document is a factual, regulatory filing disclosing a significant passive ownership stake. While not directly positive or negative for the company's operations, the presence of a large institutional investor like FMR LLC holding a substantial stake can be viewed as a neutral to slightly positive signal of long-term interest.
Positives
- The continued significant stake by a major institutional investor like FMR LLC may signal confidence in VOR Biopharma Inc.'s long-term prospects.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding VOR Biopharma Inc.'s future operations or financial performance.
Industry Context
This filing is a routine disclosure of a significant passive investment by a major asset manager in a biopharmaceutical company. It reflects ongoing institutional interest in the biotech sector, where long-term investments are common due to the nature of drug development and clinical trials.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2024-12-31 | Date of event which requires filing of this statement (ownership calculation date). |
| 2025-02-11 | Date of filing of this Schedule 13G Amendment No. 4. |
Keywords
VOR Biopharma Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, passive investment, institutional investor, biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.